Creative Consultancy Huge Launches Second Edition of Huge Moves™ Magazine Creative Consultancy Huge Launches Second Edition of Huge Moves™ Magazine

- Continued Progress in the Global Development and Commercialization of XIPERE® (known as ARCATUS® in China) -

PHILADELPHIA, Pa. and VANCOUVER, British Columbia, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce a partnership with New York Cancer & Blood Specialists (NYCBS), a group of leading community cancer centers in the United States, to evaluate the Bria-IMT™ combination with a checkpoint inhibitor in its pivotal Phase 3 registration study in advanced breast cancer patients in New York.

New Service Enhances Digital Front Door for Patients and Providers New Service Enhances Digital Front Door for Patients and Providers

Investors should be careful with these stocks, because their potential may not be as promising as their price targets suggest they are.

ST. LOUIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Stifel Financial Corp. (NYSE: SF) today announced several key hires to its Options and Equity Derivatives team, helping to enhance the depth and breadth of its product suite for institutional investors.

Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023 Ordinary Shares Will Begin Trading on a Split-Adjusted Basis on October 5, 2023

BOSTON and ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (Inhibikase or Company), a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases, today announced that risvodetinib (IkT-148009) has been granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of Multiple System Atrophy (MSA).

ACHESON, Alberta, Oct. 04, 2023 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. (“NACG” or the “Company”) (TSX:NOA) today announced the closing of its acquisition of MacKellar Group (“MacKellar”), with an effective date of October 1, 2023. Total expected consideration is $395 million (the “Consideration”), with the final Consideration amount to be determined based on MacKellar’s audited financial statements as of September 30, 2023, which will be reflected in the Company’s financial statements for the year ending December 31, 2023. The Transaction was previously announced on July 26, 2023.

SOLANA BEACH, Calif., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that H.C. Wainwright will be hosting a virtual medical expert webinar on October 11, 2023 at 12:00 p.m. Eastern Time to discuss the current treatment landscape for cancer-related anorexia and cachexia. The webinar will feature challenges and opportunities from a historical perspective and future strategies including Artelo’s lead candidate ART27.13 which is being developed as a supportive care therapy for people suffering from anorexia and weight loss associated with cancer. ARTL27.13 is currently undergoing a Phase 2a clinical trial for this potential indication.

The new larger facility will provide three new career training programs – Welding Technology, HVAC and Electrical and Electronic Systems Technology (EEST) – in addition to the Automotive Technology program offered at the current Philadelphia campus. The new larger facility will provide three new career training programs – Welding Technology, HVAC and Electrical and Electronic Systems Technology (EEST) – in addition to the Automotive Technology program offered at the current Philadelphia campus.

Celebrates recent spin-off and subsequent Nasdaq listing Celebrates recent spin-off and subsequent Nasdaq listing

ATLANTA, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company focused on meeting significant unmet needs for women worldwide with a broad portfolio of in-office, accessible solutions, including a lead late-clinical stage product candidate and innovative diagnostic products, today announced that it will be exhibiting at the annual meeting of the American Society of Reproductive Medicine (ASRM): “The Past, The Present, and The Pipeline”, being held in New Orleans, Louisiana from October 14-18, 2023.

Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors Preclinical data highlights CD27’s mechanism of action and strong anti-tumor activity as a monotherapy and in combination with other checkpoint inhibitors

-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function -- -- Weight-loss drugs like Ozempic, Wegovy, Mounjaro and other GLP-1 drugs cause a significant loss of both fat and muscle; in older obese or overweight patients who may already have low muscle mass, the further drop in muscle mass of all-important muscles increases risk of muscle weakness, functional limitations, mobility disability, falls, higher hospitalizations, and greater mortality --

Proprietary system seeks out and destroys airborne and surface-based mold, bacteria, viruses and other pathogens in real-time

SARASOTA, Fla., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Roper Technologies, Inc. (Nasdaq: ROP) announced that its financial results for the third quarter of 2023, ended September 30, 2023, will be released before the market opens on Wednesday, October 25, 2023. A conference call to discuss these results has been scheduled for 8:00 AM ET on Wednesday, October 25, 2023. The call can be accessed via webcast or by dialing +1 844-750-4898 (US/Canada) or +1 412-317-5294, using confirmation number 10182514. Webcast information and conference call materials will be made available in the Investors section of Roper’s website prior to the start of the call.

LAFAYETTE, Colo., Oct. 04, 2023 (GLOBE NEWSWIRE) -- urban-gro, Inc. (Nasdaq: UGRO) (“urban-gro” or the “Company”), an integrated professional services consulting firm, today announced that the Company signed multiple contracts representing an aggregate value of more than $4.5 million. The contracts include additional projects for an existing national US-based client within the industrial sector, as well as an awarded project with a new higher education client in the Western United States. The Company anticipates that the collective revenue for these projects will be predominantly recognized over the next two quarters.

Toll Brothers City Living Announces Two Decorated Models Are Now Open to Tour at The Rockwell on Manhattan's Upper West Side.

KANSAS CITY, KS and MIAMI, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (“Digital Ally”) and Clover Leaf Capital Corp. (Nasdaq: CLOE) (“CLOE”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement by CLOE on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”), which contains a preliminary proxy statement and prospectus in connection with the proposed business combination (the “Business Combination”), announced June 2, 2023, with Kustom Entertainment, Inc. (“Kustom Entertainment”), a wholly-owned subsidiary of Digital Ally.

TAMPA, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Superlatus, Inc. (“Superlatus”), wholly owned subsidary of TRxADE HEALTH, Inc. (NASDAQ: MEDS), a pharmaceutical exchange platform provider, entered into an all-cash asset purchase agreement to acquire the assets of Spero Foods, Inc. (“Spero”) on October 2, 2023.

Mainz Biomed Announces Live Launch of ColoAlert® with Bioclinica in Romania

With trustworthy innovation at its core, Dayforce Co-Pilot extends Ceridian’s commitment to investing in AI capabilities With trustworthy innovation at its core, Dayforce Co-Pilot extends Ceridian’s commitment to investing in AI capabilities

SEATTLE, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Kineta, Inc. (Nasdaq: KA) (the “Company” or “Kineta”), a clinical-stage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance, announced today that it has entered into a definitive agreement for the purchase and sale of 890,208 shares of the Company’s common stock (or pre-funded warrants in lieu thereof) at a purchase price of $3.37 per share of common stock (or pre-funded warrant in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered warrants to purchase up to 890,208 shares of common stock with an exercise price of $3.25 per share which will be immediately exercisable for a period of five and one-half years following issuance. The closing of the offering is expected to occur on or about October 5, 2023, subject to the satisfaction of customary closing conditions.

CHARLOTTESVILLE, Va. and INDIANAPOLIS, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD), today announced that it will present deeper insights and new exploratory findings from its Phase 1 INTERCEPT-AD trial evaluating ACU193, the first clinical-stage AβO-directed antibody therapy for early AD, at the 16th Annual Clinical Trials on Alzheimer’s Disease (CTAD) conference taking place in Boston and online from October 24-27, 2023. INTERCEPT-AD was selected to be featured in a symposium on Friday, October 27, and data from exploratory analyses of the Phase 1 trial will also be shared in two in-person and two virtual poster presentations.

A new, open marketplace to connect Dayforce capabilities across the partner, solution, and talent ecosystems A new, open marketplace to connect Dayforce capabilities across the partner, solution, and talent ecosystems

TransUnion publishes comprehensive report on consumer experiences in the gig economy TransUnion publishes comprehensive report on consumer experiences in the gig economy

PRINCETON, N.J., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release third quarter 2023 financial results on Wednesday, October 25, 2023, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.

New sales team secures over $1 Million in aggregate BARR

Virtual Webinar to Take Place October 11, 2023 at 2:00pm ET Virtual Webinar to Take Place October 11, 2023 at 2:00pm ET

HOLLYWOOD, Fla., Oct. 04, 2023 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, conformity assessment, and consulting solutions, today announced the winners of the 2023 NV5 National Society of Black Engineers (NSBE) scholarship awards. The ten scholarship awards are part of NV5’s five-year $275,000 commitment to NSBE.

BigBear.ai’s Simulation for AutoCAD Showcased by Autodesk CEO

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that new clinical and pre-clinical data for its BRG1/BRM inhibitor FHD-286, pre-clinical data for its selective EP300 program, and pre-clinical data for its BRD9 degrader FHD-609, will be presented at the AACR-NCI-EORTC International Conference. The conference will be held October 11–15, 2023, in Boston, Massachusetts.

Draganfly CEO Cameron Chell will provide expertise and insights into how Draganfly’s drone technology has enhanced disaster management efforts.

MONTREAL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- PyroGenesis Canada Inc. (http://pyrogenesis.com) (NASDAQ: PYR) (TSX: PYR) (FRA: 8PY), a high-tech Company (the “Company” or “PyroGenesis”) that designs, develops, manufactures and commercializes advanced plasma processes and sustainable solutions which are geared to reduce greenhouse gases (GHG) and address environmental pollutants, is pleased to announce today that it has received acceptance from the Toronto Stock Exchange (“TSX”) of its Notice of Intention to implement a Normal Course Issuer Bid (“NCIB”).

This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14, 2021.

New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained Providers New Relationships Expected to Add Potentially Significant New Revenue Opportunities for Vivos as well as Airway-Focused Expertise and Potential Cost Savings for Vivos-trained Providers

MONTREAL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Vision Marine Technologies Inc. (NASDAQ: VMAR) (“Vision Marine” or the “Company”), a global leader and innovator within the performance electric recreational boating industry, is pleased to announce the delivery of its pioneering E-Motion™ Electric Powertrain Technology to Groupe Beneteau, Four Winns at their production facility in Michigan. These will be the inaugural electric motors integrated on the Four Winns H2e Bowrider. (https://www.fourwinns.com/intl/boat/h2e)

– Presentations to highlight preclinical data supporting combination of KO-2806 with targeted therapies, including TKIs, KRASG12C inhibitors and KRASG12D inhibitors –

KANSAS CITY, KS and MIAMI, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Digital Ally, Inc. (Nasdaq: DGLY) (“Digital Ally”) and Clover Leaf Capital Corp. (Nasdaq: CLOE) (“CLOE”), a publicly traded special purpose acquisition company, today announced the filing of a registration statement by CLOE on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”), which contains a preliminary proxy statement and prospectus in connection with the proposed business combination (the “Business Combination”), announced June 2, 2023, with Kustom Entertainment, Inc. (“Kustom Entertainment”), a wholly-owned subsidiary of Digital Ally.

Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trials Targeting biotech companies with drug production process development and optimization, analytical methods development, and GMP production for clinical trials

Le présent communiqué de presse constitue un « communiqué désigné » aux fins du supplément de prospectus de la Société daté du 16 décembre 2021 à son prospectus préalable de base simplifié daté du 14 décembre 2021.

GARDEN CITY, N.Y. and HAMILTON, Bermuda, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric oxide (UNO) as an immunotherapeutic for solid tumors, today announced that Beyond Cancer, Ltd. will present two proffered posters at the upcoming American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer (AACR-NCI-EORTC) International Conference on Molecular Targets and Cancer Therapeutics 2023, which is scheduled to be held October 11th – 15th in Boston, Massachusetts. Abstracts are scheduled to be released to AACR-NCI-EORTC registrants today 12:00 pm U.S. ET.

New York, NY, Oct. 04, 2023 (GLOBE NEWSWIRE) -- BioPlus Acquisition Corp. (“BIOS” or the “Company”) (Nasdaq: BIOS) announced today that (i) BIOS, Avertix Medical, Inc. and certain other parties have mutually agreed to terminate their previously announced business combination agreement and plan of reorganization (the “Business Combination Agreement”), effective as of October 4, 2023 and (ii) it intends to liquidate as soon as practicable after October 4, 2023 and to return funds to holders of its Class A ordinary shares that were included in the units issued in the Company’s initial public offering (“Public Shares”).

CHANTILLY, Va., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Parsons Corporation (NYSE:PSN) will release third quarter 2023 financial results before the markets open on Wednesday, November 1, 2023. The company will host a conference call at 8:00 a.m. Eastern Time that day to discuss its earnings results and strategic corporate initiatives.

Brain inflammation from traumatic injury releases proinflammatory cytokines that activate inflammasomes in the heart leading to damaging inflammation.

TULSA, Okla., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Matrix Service Company (Nasdaq: MTRX), a leading contractor to the energy and industrial markets across North America, today released its Fiscal 2023 Sustainability Report.